Contribution of MSH2, MLH1, MSH6 and TGFBR2 germline mutations to colorectal cancer susceptibility and its prevalence.

被引：0
|
作者：
Lagarde, AE
Baumann, E
Danis, L
Stem, HS
机构：
[1] Ottawa Hlth Res Inst, Ottawa, ON, Canada
[2] Univ Ottawa, Dept Surg, Ottawa, ON, Canada
[3] Ottawa Canc Ctr, Ottawa, ON, Canada
来源：
AMERICAN JOURNAL OF HUMAN GENETICS | 2002年 / 71卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
363
引用
收藏
页码：234 / 234
页数：1
相关论文
共 50 条
  • [31] Incidence of hereditary nonpolyposis colorectal carcinoma-related cancer in clinically ascertained MLH1, MSH2 and MSH6 families
    Ramsoekh, D.
    van Leerdam, M. E.
    Wagner, A.
    Dooijes, D.
    Tops, C.
    Kuipers, E. J.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2008, 20 (07) : A26 - A27
  • [32] Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma
    Stark, Andreas M.
    Doukas, Alexander
    Hugo, Heinz-Herrmann
    Hedderich, Juergen
    Hattermann, Kirsten
    Mehdorn, H. Maximilian
    Held-Feindt, Janka
    NEUROLOGICAL RESEARCH, 2015, 37 (02) : 95 - 105
  • [33] Topography immunohistochemical markers in pancreatic ductal adenocarcinoma: Application of MSH2, MSH6, MLH1
    Nyuganen, A.
    Kudaybergenova, A.
    Ivko, O.
    Pokataev, I.
    Semenova, T.
    Artemyeva, A.
    VIRCHOWS ARCHIV, 2017, 471 : S190 - S190
  • [34] Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome
    Engel, Christoph
    Ahadova, Aysel
    Seppala, Toni T.
    Aretz, Stefan
    Bigirwamungu-Bargeman, Marloes
    Blaeker, Hendrik
    Bucksch, Karolin
    Buettner, Reinhard
    Cappel, Wouter T. De Vos Tot Nederveen
    Endris, Volker
    Holinski-Feder, Elke
    Holzapfel, Stefanie
    Hueneburg, Robert
    Jacobs, Maarten A. J. M.
    Koornstra, Jan J.
    Langers, Alexandra M.
    Lepisto, Anna
    Morak, Monika
    Moeslein, Gabriela
    Peltomaeki, Paivi
    Pylvaenaeinen, Kirsi
    Rahner, Nils
    Renkonen-Sinisalo, Laura
    Schulmann, Karsten
    Steinke-Lange, Verena
    Stenzinger, Albrecht
    Strassburg, Christian P.
    van de Meeberg, Paul C.
    van Kouwen, Mariette
    van Leerdam, Monique
    Vangala, Deepak B.
    Vecht, Juda
    Verhulst, Marie-Louise
    Doeberitz, Magnus von Knebel
    Weitz, Juergen
    Zachariae, Silke
    Loeffler, Markus
    Mecklin, Jukka-Pekka
    Kloor, Matthias
    Vasen, Hans F.
    GASTROENTEROLOGY, 2020, 158 (05) : 1326 - 1333
  • [35] The frequency of MLH1 and MSH2 germline mutations in colorectal cancer patients met the revised Bethesda Guidelines
    Lyubchenko, L.
    Semyanikhina, A.
    Pospekhova, N.
    Golovina, D.
    Rasulov, A.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1556 - 1557
  • [36] MISMATCH REPAIR PROTEINS (MLH1, MSH2, MSH6) AS A PREDICTIVE MARKER FOR RADIOSENSITIVITY IN RECTAL CANCER.
    Park, C.
    Kim, H.
    DISEASES OF THE COLON & RECTUM, 2010, 53 (04) : 613 - 613
  • [37] Colorectal cancer cases with de novo germ-line mutations in MLH1, MSH2, and MSH6 from the Colon Cancer Family Registry.
    Win, A. K.
    Jenkins, M. A.
    Buchanan, D. D.
    Young, J. P.
    Thibodeau, S. N.
    Hopper, J. L.
    Lindor, N. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] MSH2 and MLH1 testing
    Grzegorz Kurzawski
    Janina Suchy
    Jan Lubiński
    Hereditary Cancer in Clinical Practice, 6
  • [39] Cancer risks associated with germline mutations in MLH1, MSH2 and MSH6 genes in Lynch syndrome: results from the large nationwide French ERISCAM study
    Bonadona, Valerie
    Bonaiti, Bernard
    Olschwang, Sylvianne
    Grandjouan, Sophie
    Wang, Qing
    Bonaiti-Pellie, Catherine
    Lasset, Christine
    BULLETIN DU CANCER, 2011, 98 : S84 - S85
  • [40] Correlation between clinical-pathological parameters and family history to detect mutations in MLH1, MSH2, and MSH6
    Guillen-Ponce, C.
    Castillejo, A.
    Barbera, V. M.
    Alenda, C.
    Molina-Garrido, M.
    Carrato, A.
    Soto, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345